Minocycline-Treatment of Diabetic Rats Normalizes Skin Collagen Production and Mass: Possible Causative Mechanisms

Daily minocycline-treatment of streptozotocin-induced diabetic rats not only prevented a diabetes-caused atrophy of skin collagen mass (IO-mos old rats), but also normalized skin collagen mass to match that of growing (ca.1 %/d) non-diabetic controls (4- and 5-mos old rats).The causative mechanism by which minocycline-treatment normalizes skin collagen mass must, in part, be related to a general anabolic effect on growth (body weight) because the effect on skin collagen mass correlates strongly to that on body weight.Consequently, a minocycline-stimulated increase of a systemic factor (such as insulin-like growth factor) is not unlikely.The anabolic effect of minocycline-treatment of diabetic rats is also expressed as a normalized cellular ribosome mass (an index of total protein synthetic capacity) and a normalized absolute rate of collagen production.(Calculation of an absolute rate was justified by an apparent maximum saturation of the prolyl-tRNA pool(s) of skin, maximum saturation obtained by the pool-flooding approach.) The normalized skin ribosome amount does not, however, explain a selective effect of minocylcine-treatment on collagen production as opposed to that for non-collagen protein, this selective effect measured as relative collagen production.To explain such selectivity, the inhibition of diabetes-induced excess skin collagenase activity seems unlikely.(This inference is based on results from a preliminary study indicating that recently [2 hs] synthesized collagen is not degraded by the excess collagenase in skin of diabetic rats.) Thus, the principal collagen fraction acted on by pathologically excess collagenase might be collagen at a later stage (> 2 h after synthesis) in its life cycle.(Another possibility for the selective effect of minocycline on collagen production, as yet untested, is reduced intracellular pro collagen degradation.) Overall, this is the first study aimed at discerning the mechanism(s) by which minocyclinetreatment enhances the rate of collagen production in tissues of a diabetic rat.For future studies, the extent to which the positive effect on growth, ribosome mass, and rate of collagen production contributes to the change of collagen mass must, along with the known minocycline-inhibition of collagenase activity, be quantified.Such quantification is a prerequisite for evaluating the chemotherapeutic efficacy of minocycline-treatment on collagen-degradative diseases.